A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

NCT06793709 · clinicaltrials.gov ↗

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

OTHER: No Intervention

Sponsor

Eisai Co., Ltd.